L
Lyell Immunopharma, Inc. (LYEL)
NMS – Real vaqt narxi. Valyuta: USD
19.25
+0.05 (0.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
19.25
+0.05 (0.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Lyell Immunopharma, Inc., klinik bosqichdagi hujayrali terapiya kompaniyasi, gematologik o'smalar va qattiq o'smalarga chalingan bemorlar uchun ximerik antigen retseptorlari (CAR) T-hujayrali mahsulot nomzodlarini ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodlari orasida rondecabtagene autoleucel mavjud bo'lib, bu ishlab chiqilayotgan avtologik er-xotin-maqsadli CD19/CD20 CAR T-hujayrali terapiyasi bo'lib, u 3L+ sharoitida PiNACLE asosiy tadqiqotida va 2L sharoitida 1/2-faza klinik tadqiqotida, shuningdek, ikkinchi PiNACLE-H2H asosiy tadqiqotida, bu katta B-hujayrali limfomani davolash uchun 2L sharoitida LBCL uchun ronde-celni boshma-bosh CAR T-hujayrali terapiyasini qiyosiy randomizatsiyalangan nazoratli 3-faza tadqiqoti hisoblanadi; hamda LYL273, GCC-maqsadli CAR T-hujayrali mahsulot nomzodi bo'lib, CD19 CAR ekspressiyasi va nazorat qilinadigan sitokin chiqarilishi bilan kuchaytirilgan bo'lib, CAR T-hujayralarining kengayishini, immunitet hujayralarining infiltratsiyasini va qattiq o'simtalarning qiyin mikro-muhitida saraton hujayralarining o'limini yaxshilash uchun mo'ljallangan bo'lib, u refrakter metastatik kolorektal rakni davolash uchun 1-faza klinik tadqiqotida. Kompaniya turli xil yondashuvlardan foydalangan holda terapiyalarni ishlab chiqadi, masalan, c-Junning ortiqcha ekspressiyasi va NR4A3 genining nokauti, charchoqqa qarshi funktsional qarshilikni ta'minlash; Epi‑R bilan kamroq charchoq va yaxshilangan proliferatsiya va o'simtaga qarshi faollikka ega bo'lgan ildiz hujayrali T-hujayralar populyatsiyasini yaratish; va CD62L ijobiy boyitish bilan o'simtaga qarshi faolligi oshirilgan CAR T-hujayralarini yaratish. Lyell Immunopharma, Inc. 2018 yilda tashkil etilgan va shtab-kvartirasi Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor |
| Dr. Gary K. Lee Ph.D. | Chief Scientific Officer |
| Dr. Lynn Seely M.D., Ph.D. | Principal Executive Officer, President, CEO & Director |
| Dr. Richard D. Klausner M.D. | Founder & Executive Chairman |
| Mr. Mark A. Meltz J.D. | General Counsel & Corporate Secretary |
| Mr. Stephen J. Hill | Chief Operating Officer |
| Ms. Ann Tomlin | Chief Human Resources Officer |
| Ms. Smital Shah M.B.A. | Principal Financial Officer, CFO & Chief Business Officer |
| Nellie Dillery | Director of Accounting |
| Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | lyel-20260506.htm |
| 2026-04-24 | DEFA14A | ny20068007x2_defa14a.htm |
| 2026-04-24 | ARS | ny20068007x3_ars.pdf |
| 2026-04-03 | S-3 | d122816ds3.htm |
| 2026-03-12 | 10-K | lyel-20251231.htm |
| 2026-03-09 | 8-K | d84786d8k.htm |
| 2025-12-08 | 8-K | d35459d8k.htm |
| 2025-12-05 | S-3 | d72300ds3.htm |
| 2025-11-12 | 10-Q | lyel-20250930.htm |
| 2025-11-10 | 8-K | d57756d8k.htm |